InterPAD - DETAILS

VERAPAMIL, 52-53-9, Iproveratril, Dilacoran, Vasolan, Isoptimo, Isoptin, Verapamilo, Verapamilum, Falicard, Finoptin, Calan, Lekoptin, Isoptine, D-365, Verapamilum [INN-Latin], Verapamilo [INN-Spanish], Isotopin, Securon, Calcan, Tarka, CP-16533-1, dl-Verapamil, (+/-)-VERAPAMIL, r,s-verapamil, Izoptin, Verelan, Verapamil slow release, CCRIS 6749, Covera-HS, 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile, 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile, 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile, Ansyr, EINECS 200-145-1, UNII-CJ0O37KU29, Verpamil, CJ0O37KU29, Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, Isoptin SR, Verelan PM, NSC 272306NA, Calan SR, CP-16,533-1, 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile, EINECS 260-462-6, alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile, alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile, CP-165331, Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-, alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile, CP 16533-1, D 365, DTXSID9041152, CHEBI:77733, HSDB 3928, NSC-272306NA, Veratensin, Anpec, Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, Verapamil AL, NCGC00016083-09, Verapamilum (INN-Latin), Verapamilo (INN-Spanish), 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile, Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, (+/-)-Verapamil hydrochlorid, CP-165331 / CP-16533-1, DTXCID7021152, Verapamil [USAN:INN:BAN], (+/-)-Verapamil;CP-16533-1, CAS-52-53-9, (+/-)-5-((3,4-DIMETHOXYPHENETHYL)METHYLAMINO)-2-(3,4-DIMETHOXYPHENYL)-2-ISOPROPYLVALERONITRILE, C27H38N2O4, Verapamil (USAN/INN), ?Verapamil, Calan (Salt/Mix), Akilen (Salt/Mix), Verapamilum (Latin), Isoptin (Salt/Mix), Cordilox (Salt/Mix), delta-365, alpha-isopropyl-alpha-, VERAPAMIL [INN], VERAPAMIL [MI], Covera-HS (Salt/Mix), VERAPAMIL [USAN], Prestwick0_000141, Prestwick1_000141, Prestwick2_000141, Prestwick3_000141, Spectrum2_001740, Spectrum4_000906, Spectrum5_001786, VERAPAMIL [VANDF], ()-Verapamil hydrochlorid, VERAPAMIL [WHO-DD], CHEMBL6966, Lopac0_001237, SCHEMBL16742, BSPBio_000242, BSPBio_001513, BSPBio_002358, KBioGR_000233, KBioGR_001372, KBioGR_002343, KBioSS_000233, KBioSS_002346, 56949-77-0, MLS006011414, DivK1c_000399, SPBio_001820, SPBio_002181, BPBio1_000268, CHEBI:9948, GTPL2406, CP 16533-1 (Verapamil), SCHEMBL13287282, (A+/-)-Verapamil hydrochloride, BDBM81939, KBio1_000399, KBio2_000233, KBio2_002343, KBio2_002801, KBio2_004911, KBio2_005369, KBio2_007479, KBio3_000465, KBio3_000466, KBio3_002823, C08DA01, ()-Verapamil;CP-16533-1, cMAP_000023, NINDS_000399, Bio1_000425, Bio1_000914, Bio1_001403, Bio2_000233, Bio2_000713, DTXSID501009404, HMS1791L15, HMS1989L15, HMS2089H17, HMS3402L15, Tox21_110300, MFCD00056240, NSC_62969, STK538085, AKOS005468962, Tox21_110300_1, CCG-205311, DB00661, SDCCGSBI-0051204.P005, CAS_52-53-9, IDI1_000399, IDI1_033983, NCGC00016083-04, NCGC00016083-05, NCGC00016083-06, NCGC00016083-07, NCGC00016083-08, NCGC00016083-10, NCGC00016083-11, NCGC00016083-13, NCGC00016083-14, NCGC00016083-15, NCGC00016083-16, NCGC00016083-17, NCGC00016083-18, NCGC00016083-20, NCGC00016083-25, NCGC00016083-34, NCGC00024710-04, NCGC00024710-05, NCGC00024710-06, NCGC00024710-07, NCGC00024710-08, NCGC00024710-09, NCGC00344584-01, 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile, 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile, AC-16016, BP-21223, HY-14275, NCI60_020143, SMR001550201, SBI-0051204.P003, (-)-3-(3,4-dimethoxyphenyl)-6-[(5,6-dimethoxyphenethyl)methylamino]hexane-3-carbonitrile, DB-349548, AB00053495, CS-0002967, NS00000313, C07188, D02356, E75969, EN300-708774, AB00053495-20, AB00053495_21, A829133, L001330, Q410291, BRD-A09533288-001-02-7, BRD-A09533288-003-05-6, F2173-0851, VERAPAMIL, Dexverapamil, Verapamyl hydrochloride, VERAPAMIL HYDROCHLORIDE, .alpha.-((N-Methyl-N-homoveratryl)-.gamma.-aminopropyl)-3,4-dimethoxyphenylacetonitrile, 2-(3,4-Dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-isopropylpentanenitrile, (+/-)-, 2-(3,4-Dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-isopropylpentanenitrile #, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-benzeneacetonitrile, alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile, rac-2-(3,4-dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-(propan-2-yl)pentanenitrile

Name	Verapamil
PubChem CID	2520
Molecular Weight	454.6g/mol
Synonyms	VERAPAMIL, 52-53-9, Iproveratril, Dilacoran, Vasolan, Isoptimo, Isoptin, Verapamilo, Verapamilum, Falicard, Finoptin, Calan, Lekoptin, Isoptine, D-365, Verapamilum [INN-Latin], Verapamilo [INN-Spanish], Isotopin, Securon, Calcan, Tarka, CP-16533-1, dl-Verapamil, (+/-)-VERAPAMIL, r,s-verapamil, Izoptin, Verelan, Verapamil slow release, CCRIS 6749, Covera-HS, 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile, 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile, 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile, Ansyr, EINECS 200-145-1, UNII-CJ0O37KU29, Verpamil, CJ0O37KU29, Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, Isoptin SR, Verelan PM, NSC 272306NA, Calan SR, CP-16,533-1, 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile, EINECS 260-462-6, alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile, alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile, CP-165331, Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-, alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile, CP 16533-1, D 365, DTXSID9041152, CHEBI:77733, HSDB 3928, NSC-272306NA, Veratensin, Anpec, Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, Verapamil AL, NCGC00016083-09, Verapamilum (INN-Latin), Verapamilo (INN-Spanish), 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile, Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, (+/-)-Verapamil hydrochlorid, CP-165331 / CP-16533-1, DTXCID7021152, Verapamil [USAN:INN:BAN], (+/-)-Verapamil;CP-16533-1, CAS-52-53-9, (+/-)-5-((3,4-DIMETHOXYPHENETHYL)METHYLAMINO)-2-(3,4-DIMETHOXYPHENYL)-2-ISOPROPYLVALERONITRILE, C27H38N2O4, Verapamil (USAN/INN), ?Verapamil, Calan (Salt/Mix), Akilen (Salt/Mix), Verapamilum (Latin), Isoptin (Salt/Mix), Cordilox (Salt/Mix), delta-365, alpha-isopropyl-alpha-, VERAPAMIL [INN], VERAPAMIL [MI], Covera-HS (Salt/Mix), VERAPAMIL [USAN], Prestwick0_000141, Prestwick1_000141, Prestwick2_000141, Prestwick3_000141, Spectrum2_001740, Spectrum4_000906, Spectrum5_001786, VERAPAMIL [VANDF], ()-Verapamil hydrochlorid, VERAPAMIL [WHO-DD], CHEMBL6966, Lopac0_001237, SCHEMBL16742, BSPBio_000242, BSPBio_001513, BSPBio_002358, KBioGR_000233, KBioGR_001372, KBioGR_002343, KBioSS_000233, KBioSS_002346, 56949-77-0, MLS006011414, DivK1c_000399, SPBio_001820, SPBio_002181, BPBio1_000268, CHEBI:9948, GTPL2406, CP 16533-1 (Verapamil), SCHEMBL13287282, (A+/-)-Verapamil hydrochloride, BDBM81939, KBio1_000399, KBio2_000233, KBio2_002343, KBio2_002801, KBio2_004911, KBio2_005369, KBio2_007479, KBio3_000465, KBio3_000466, KBio3_002823, C08DA01, ()-Verapamil;CP-16533-1, cMAP_000023, NINDS_000399, Bio1_000425, Bio1_000914, Bio1_001403, Bio2_000233, Bio2_000713, DTXSID501009404, HMS1791L15, HMS1989L15, HMS2089H17, HMS3402L15, Tox21_110300, MFCD00056240, NSC_62969, STK538085, AKOS005468962, Tox21_110300_1, CCG-205311, DB00661, SDCCGSBI-0051204.P005, CAS_52-53-9, IDI1_000399, IDI1_033983, NCGC00016083-04, NCGC00016083-05, NCGC00016083-06, NCGC00016083-07, NCGC00016083-08, NCGC00016083-10, NCGC00016083-11, NCGC00016083-13, NCGC00016083-14, NCGC00016083-15, NCGC00016083-16, NCGC00016083-17, NCGC00016083-18, NCGC00016083-20, NCGC00016083-25, NCGC00016083-34, NCGC00024710-04, NCGC00024710-05, NCGC00024710-06, NCGC00024710-07, NCGC00024710-08, NCGC00024710-09, NCGC00344584-01, 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile, 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile, AC-16016, BP-21223, HY-14275, NCI60_020143, SMR001550201, SBI-0051204.P003, (-)-3-(3,4-dimethoxyphenyl)-6-[(5,6-dimethoxyphenethyl)methylamino]hexane-3-carbonitrile, DB-349548, AB00053495, CS-0002967, NS00000313, C07188, D02356, E75969, EN300-708774, AB00053495-20, AB00053495_21, A829133, L001330, Q410291, BRD-A09533288-001-02-7, BRD-A09533288-003-05-6, F2173-0851, VERAPAMIL, Dexverapamil, Verapamyl hydrochloride, VERAPAMIL HYDROCHLORIDE, .alpha.-((N-Methyl-N-homoveratryl)-.gamma.-aminopropyl)-3,4-dimethoxyphenylacetonitrile, 2-(3,4-Dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-isopropylpentanenitrile, (+/-)-, 2-(3,4-Dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-isopropylpentanenitrile #, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-benzeneacetonitrile, alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile, rac-2-(3,4-dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-(propan-2-yl)pentanenitrile
Drug Type	Small molecule
Formula	C₂₇H₃₈N₂O₄
SMILES	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
InChI	1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
InChIKey	SGTNSNPWRIOYBX-UHFFFAOYSA-N
CAS Number	52-53-9
ChEMBL ID	CHEMBL6966
ChEBI ID	CHEBI:77733
TTD ID	D0R0FE
Drug Bank ID	DB00661
KEGG ID	C07188
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Kaempferol, Verapamil
Partner Name	Kaempferol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->ROS generation
Gene Regulation	Up-regulation	Expression	MAP1LC3B	hsa81631
Gene Regulation	Up-regulation	Expression	SQSTM1	hsa8878
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	Kaempferol with Verapamil impeded panoramic chemoevasion pathways in breast cancer through ROS overproduction and disruption of lysosomal biogenesis

Pair Name	Kaempferol, Verapamil
Partner Name	Kaempferol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Expression	ABCB1	hsa5243
	Down-regulation	Expression	CD44	hsa960
	Down-regulation	Expression	NANOG	hsa79923
	Down-regulation	Expression	POU5F1	hsa5460
	Down-regulation	Expression	SOX2	hsa6657
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil

No.	Title	Href
1	Kaempferol with Verapamil impeded panoramic chemoevasion pathways in breast cancer through ROS overproduction and disruption of lysosomal biogenesis. Phytomedicine. 2023 May;113:154689. doi: 10.1016/j.phymed.2023.154689.	`Click`
2	Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicol Appl Pharmacol. 2022 Feb 15;437:115887. doi: 10.1016/j.taap.2022.115887.	`Click`